Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01432080
Other study ID # HMR1102
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date September 2011
Est. completion date December 30, 2013

Study information

Verified date October 2021
Source Maisonneuve-Rosemont Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

For many patients with blood cancers, stem cell transplantation from a family member or from an unrelated donor remains the only potentially curative option. Unfortunately, up to 40% of patients develop chronic lung disease after the transplant, which substantially increases the risk of death in the long-term. Currently, patients with transplant-related lung disease are treated with some combination of steroids and other immunosuppressant drugs, but only about 1 out of 5 improve. The importance of our study is that the investigators aim to prevent the development of transplant-related chronic lung disease in the first place. Because a strong risk factor for such chronic lung disease is a prior viral respiratory tract infection, the investigators think there is a window of opportunity to intervene. As soon as "cold and flu" symptoms start, the investigators will treat patients with a combination of drugs aimed at eliminating damaging immune responses triggered by the virus. In the absence of such treatment, the investigators believe these lung-damaging immune responses would persist even after the virus disappears. Our hope is that preventive treatment might avoid the development of chronic lung disease, and this would substantially increase long-term survival in our transplant patients. This is a pilot study. Once feasibility is established, the investigators will seek to expand this study into a definitive clinical trial.


Recruitment information / eligibility

Status Terminated
Enrollment 12
Est. completion date December 30, 2013
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Allogeneic transplant within the prior 1 year - Age greater than or equal to 18 years - Capable of informed consent - Neutrophil engraftment has occurred - This is the first clinically-recognized episode of viral respiratory tract infection after transplant Exclusion Criteria: - Proof or high suspicion for bacterial, fungal or any non-viral microorganism causing pneumonia - CMV, VZV or HSV pneumonia - Prior diagnosis of a chronic transplant-related non-infectious pulmonary complication (ex: BO, COP) - Treating physician believes the risk of systemic steroids is too great - Currently receiving prednisone at or greater than 0.25 mg/kg/day or the equivalent dose of another steroid - Currently receiving pentostatin - Mycophenolate initiated de novo or increased within the past 4 weeks - Use of inhaled corticosteroids within the past 2 weeks for at least 1 week - Haploidentical or T-cell depleted graft - Lack of pre-transplant pulmonary function tests - Evidence of a prior symptomatic viral respiratory tract infection following transplant, whether treated or not - Allergy or adverse reaction to any of the study drugs - Relapse or progression of the underlying malignancy - Palliative care

Study Design


Intervention

Drug:
Prednisone
Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
Azithromycin
Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
Montelukast
Montelukast 10 mg PO qhs for 3 months
Symbicort
Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months

Locations

Country Name City State
Canada Maisonneuve-Rosemont Hospital (Hôpital Maisonneuve-Rosemont) Montreal Quebec

Sponsors (2)

Lead Sponsor Collaborator
Maisonneuve-Rosemont Hospital The Canadian Blood and Marrow Transplant Group

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative incidence of new chronic lung disease The incidence rate of new non-infectious pulmonary complications within the 6 month follow-up period will be calculated. Non-infectious pulmonary complications include new airflow obstruction, new restrictive lung disease, and new mixed obstruction/restriction as measured by spirometry at study enrolment, 2 and 8 weeks following viral infection, and by full pulmonary function tests at 3 and 6 weeks following viral infection. 6 months following diagnosis of the viral respiratory tract infection
Secondary Prevalence of non-infectious pulmonary complications Non-infectious pulmonary complications (NIPCs) include airflow obstruction, restrictive lung disease, and mixed obstruction/restriction as determined by pulmonary function tests. The prevalence of NIPCs will be determined among subjects surviving to 6 months post viral respiratory tract infection. 6 months following the diagnosis of viral respiratory tract infection
Secondary Long-term functional impairment as defined by need for supplemental oxygen The percentage of subjects needing at least 1 month of supplemental oxygen on most days per week, not counting the period of symptomatic viral respiratory tract infection, will be determined in both arms. 6 months post viral respiratory tract infection
Secondary Patient-perceived long-term functional impairment A FACT-BMT questionnaire will be administered at baseline and again to subjects surviving 6 months post respiratory tract infection to measure patient-perceived functional impairment. 6 months post viral respiratory tract infection
Secondary Time to clearance of viral infection Subjects in whom a respiratory virus is detected will undergo repeat testing every 2 weeks until the virus is no longer detectable. This is an exploratory analysis. The natural history of many of these community-acquired viruses in the transplant population is not known. Every 2 weeks until virus is no longer detectable
Secondary Incidence of progression to respiratory failure This endpoint includes admission to hospital because of documented desaturation, need for supplemental oxygen, and need for mechanical ventilation. 21 days after enrolment
Secondary Incidence of bacterial or fungal superinfection The incidence of secondary bacterial and fungal pneumonias will be compared in the two arms, to verify that the added immunosuppression does not contribute to further infectious complications. Within 21 days after enrolment
Secondary Incidence of various other infectious complications The incidence of various other infectious complications, specifically including but not limited to CMV reactivations and CMV disease, zoster, and septicemia will be monitored in both arms. Within 6 months after enrolment
Secondary Overall survival from date of viral respiratory tract infection 3 months post enrolment
Secondary Overall survival from date of viral respiratory tract infection 6 months post enrolment
Secondary Overall survival from date of transplant to end of study follow-up 6 months post enrolment
Secondary Overall survival at 1 year post-transplant This measure will be applied to the group overall and also analyzed according to subgroups of patients presenting viral respiratory tract infections within 30 days of transplant, 31-100 days of transplant, and 101-365 days of transplant. 1 year post-transplant
Secondary Cumulative incidence of death attributable to transplant associated lung disease 6 months post enrolment
Secondary Cumulative incidence of death from other causes 6 months post enrolment
See also
  Status Clinical Trial Phase
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Terminated NCT04583280 - A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) Phase 3
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Active, not recruiting NCT03251196 - TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB
Completed NCT02561871 - A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers Phase 1
Terminated NCT02032056 - Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period N/A
Completed NCT01911143 - A Retrospective, Blinded Validation of a Host-response Based Diagnostics N/A
Completed NCT01419262 - DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers Phase 3
Completed NCT00984945 - Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults Phase 1
Completed NCT00127686 - Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep Phase 1
Active, not recruiting NCT01107223 - Long Term Effect of General Practitioner Education on Antibiotic Prescribing N/A
Completed NCT03739112 - Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly Phase 3
Completed NCT04144491 - Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda N/A
Completed NCT05318235 - Virus Interactions in the Respiratory Tract; a Cohort Study With Children
Active, not recruiting NCT04170348 - Daily Vitamin D for Sickle-cell Respiratory Complications Phase 2
Completed NCT04525040 - ProbioKid as Prevention Among Kids With Frequent URTI N/A
Completed NCT05535777 - Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS) N/A
Not yet recruiting NCT05914324 - Outpatient Pediatric Pulse Oximeters in Africa N/A
Completed NCT04533685 - Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- UCLA Portal R/R Influenza RCT 3 N/A